Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 1 of 4: Relative cell counts and normalized growth rate inhibition values across technical replicates. - Dataset (ID:20268)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Clinical Subtype | Transcriptional Subtype | Small Molecule | Antibody | Perturbagen Target | Perturbagen Class | Perturbagen Concentration | Perturbagen Conc Unit | Biological Replicate ID | Relative Cell Count | Normalized Growth Rate Inhibition Value | Nominal Division Rate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MDA-MB-415 | HR+ | Luminal | Lapatinib | EGFR/HER2 | ErbB | 0.0267 | uM | 7511.098 | 0.9810 | 0.9683 | 1.2032 | |
| MDA-MB-415 | HR+ | Luminal | Lapatinib | EGFR/HER2 | ErbB | 0.133 | uM | 7511.098 | 0.9511 | 0.9183 | 1.2032 | |
| MDA-MB-415 | HR+ | Luminal | Lapatinib | EGFR/HER2 | ErbB | 0.667 | uM | 7511.098 | 0.9788 | 0.9647 | 1.2032 | |
| MDA-MB-415 | HR+ | Luminal | Lapatinib | EGFR/HER2 | ErbB | 3.33 | uM | 7511.098 | 0.9871 | 0.9785 | 1.2032 | |
| MDA-MB-415 | HR+ | Luminal | Lapatinib | EGFR/HER2 | ErbB | 16.7 | uM | 7511.098 | 0.9771 | 0.9618 | 1.2032 | |
| MDA-MB-415 | HR+ | Luminal | Lapatinib | EGFR/HER2 | ErbB | 0.0000427 | uM | 7512.098 | 0.9969 | 0.9934 | 0.9499 | |
| MDA-MB-415 | HR+ | Luminal | Lapatinib | EGFR/HER2 | ErbB | 0.000213 | uM | 7512.098 | 0.9485 | 0.8918 | 0.9499 | |
| MDA-MB-415 | HR+ | Luminal | Lapatinib | EGFR/HER2 | ErbB | 0.00107 | uM | 7512.098 | 0.9724 | 0.9420 | 0.9499 | |
| MDA-MB-415 | HR+ | Luminal | Lapatinib | EGFR/HER2 | ErbB | 0.00533 | uM | 7512.098 | 0.9370 | 0.8675 | 0.9499 | |
| MDA-MB-415 | HR+ | Luminal | Lapatinib | EGFR/HER2 | ErbB | 0.0267 | uM | 7512.098 | 0.9658 | 0.9280 | 0.9499 | |
| MDA-MB-415 | HR+ | Luminal | Lapatinib | EGFR/HER2 | ErbB | 0.133 | uM | 7512.098 | 0.9350 | 0.8633 | 0.9499 | |
| MDA-MB-415 | HR+ | Luminal | Lapatinib | EGFR/HER2 | ErbB | 0.667 | uM | 7512.098 | 0.9263 | 0.8452 | 0.9499 | |
| MDA-MB-415 | HR+ | Luminal | Lapatinib | EGFR/HER2 | ErbB | 3.33 | uM | 7512.098 | 0.9699 | 0.9367 | 0.9499 | |
| MDA-MB-415 | HR+ | Luminal | Lapatinib | EGFR/HER2 | ErbB | 16.7 | uM | 7512.098 | 1.0282 | 1.0594 | 0.9499 | |
| MDA-MB-453 | TNBC | Luminal | Lapatinib | EGFR/HER2 | ErbB | 0.0000427 | uM | 7515.098 | 0.9429 | 0.9000 | 1.1465 | |
| MDA-MB-453 | TNBC | Luminal | Lapatinib | EGFR/HER2 | ErbB | 0.000213 | uM | 7515.098 | 0.8971 | 0.8192 | 1.1465 | |
| MDA-MB-453 | TNBC | Luminal | Lapatinib | EGFR/HER2 | ErbB | 0.00107 | uM | 7515.098 | 1.0516 | 1.0898 | 1.1465 | |
| MDA-MB-453 | TNBC | Luminal | Lapatinib | EGFR/HER2 | ErbB | 0.00533 | uM | 7515.098 | 1.0857 | 1.1487 | 1.1465 | |
| MDA-MB-453 | TNBC | Luminal | Lapatinib | EGFR/HER2 | ErbB | 0.0267 | uM | 7515.098 | 1.0065 | 1.0113 | 1.1465 | |
| MDA-MB-453 | TNBC | Luminal | Lapatinib | EGFR/HER2 | ErbB | 0.133 | uM | 7515.098 | 0.9760 | 0.9580 | 1.1465 | |
| MDA-MB-453 | TNBC | Luminal | Lapatinib | EGFR/HER2 | ErbB | 0.667 | uM | 7515.098 | 0.9031 | 0.8299 | 1.1465 | |
| MDA-MB-453 | TNBC | Luminal | Lapatinib | EGFR/HER2 | ErbB | 3.33 | uM | 7515.098 | 0.7931 | 0.6339 | 1.1465 | |
| MDA-MB-453 | TNBC | Luminal | Lapatinib | EGFR/HER2 | ErbB | 16.7 | uM | 7515.098 | 0.7184 | 0.4989 | 1.1465 | |
| MDA-MB-453 | TNBC | Luminal | Lapatinib | EGFR/HER2 | ErbB | 0.0000427 | uM | 7516.098 | 0.9788 | 0.9663 | 1.2625 | |
| MDA-MB-453 | TNBC | Luminal | Lapatinib | EGFR/HER2 | ErbB | 0.000213 | uM | 7516.098 | 0.8975 | 0.8359 | 1.2625 |